+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

  • ID: 4900217
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 70 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
  • MORE
Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

Summary

According to the recently published report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 9 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 6 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders and Oncology which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Uveitis, Vitiligo, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
  • MORE
Introduction
Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Palatin Technologies Inc
SolaranRx Inc
SynAct Pharma AB
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-1177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
Nov 11, 2019: SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
Oct 30, 2019: CLINUVEL: TGA Priority Registration Pathway for Scenesse
Oct 17, 2019: Palatin presents on Pl8177 oral colon delivery formulation for Ulcerative Colitis at The 7Th CPC Symposium On Peptide Therapeutics
Oct 10, 2019: Clinuvel obtains US approval for rare disorder drug Scenesse
Oct 02, 2019: FDA clarifies Scenesse PDUFA Date
Oct 01, 2019: Redeye initiates coverage of SynAct Pharma
Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)
Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse
Sep 10, 2019: SCENESSE presented at ICPP in Milan
Aug 06, 2019: Palatin Technologies to present data on anti-inflammatory drug PL-8177 at Canaccord Genuity's 39th Annual Growth Conference
Jul 17, 2019: Mallinckrodt ends Acthar Gel’s Phase IIb trial in ALS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aequus BioPharma Inc, H2 2019
Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2019
Pipeline by Eton Pharmaceuticals Inc, H2 2019
Pipeline by Palatin Technologies Inc, H2 2019
Pipeline by SolaranRx Inc, H2 2019
Pipeline by SynAct Pharma AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aequus BioPharma Inc
  • Clinuvel Pharmaceuticals Ltd
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
Note: Product cover images may vary from those shown
Adroll
adroll